A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer

British Journal of Cancer

Volumn 91, Issue 4, 2004, Pages 627-632

  Harries, M ^a   Moss, C ^a   Perren, T ^b   Gore, M ^a   Hall, G ^b   Everard, M ^a   A'Hern, R ^a   Gibbens, I ^a   Jenkins, A ^b   Shah, R ^a   Cole, C ^a   Pizzada, O ^b   Kaye, S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Carboplatin; Feasibility; Gemcitabine ovarian cancer; Sequential paclitaxel

Indexed keywords

CARBON MONOXIDE; CARBOPLATIN; GEMCITABINE; PACLITAXEL; TAXANE DERIVATIVE; TUMOR ANTIGEN;

ADULT; AGED; ALOPECIA; ANEMIA; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSE RESPONSE; DYSPNEA; EVALUATION; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FOLLOW UP; HUMAN; INFECTION; LETHARGY; LUNG DIFFUSION CAPACITY; LUNG DISEASE; LUNG TOXICITY; MAJOR CLINICAL STUDY; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIOLOGY; STOMATITIS; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TOXICITY; VOMITING;

EID: 4344564261     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602000     Document Type: Article

References (25)

1. Alberts DS (1995) Carboplatin versus cisplatin in ovarian cancer. Semin Oncol 22: 88-90
2. Bhatia S, Hanna N, Ansari R, Pletcher W, Einhorn L, Ng E, Sandler A (2002) A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer. Lung Cancer 38: 73-77
3. Cassinelli G, Supino R, Perego P, Polizzi D, Lanzi C, Pratesi G, Zunino F (2001) A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes. Int J Cancer 92: 738-747
4. D'Agostino G, Amant F, Berteloot P, Scambia G, Vergote I (2003) Phase II study of gemcitabine in recurrent platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 88: 266-269
5. Du Bois A, Neijt JP, Thigpen JT (1999) First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer - a new standard of care? Ann Oncol 10: 35-41
6. Friedlander M, Millward MJ, Bell D, Bugat R, Harnett P, Moreno JA, Campbell L, Varette C, Ripoche V, Kayitalire L (1998) A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 9: 1343-1345
7. Hansen SW (2002) Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma. Semin Oncol 29: 17-19
8. Hansen SW, Anderson H, Boman K, Hansen M, Havsteen H, Rosenberg P, Sørensen PG, Vergote I (1999) Gemcitabine, carboplatin, and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages II-IV. Pro Am Soc Clin Oncol 18, (abst 1379)
9. Harries M, Gore M (2002) Chemotherapy for epithelial ovarian cancer - Part I. Treatment at first diagnosis. Lancet Oncol 3: 529-536
10. ICON group (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360: 505-515
11. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP (1994) Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86: 1530-1533
12. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6
13. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM (2000) Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 18: 106-115
14. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol 21: 3194-3200
15. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Trope C (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361: 2099-2106
16. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin- cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92: 699-708
17. Sauer-Heilborn A, Kath R, Schneider CP, Hoffken K (1999) Severe non-haematological toxicity after treatment with gemcitabine. J Cancer Res Clin Oncol 125: 637-640
18. Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA, Toner GC (1996) Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 63: 89-93
19. Silver DF, Piver MS (1999) Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum. Am J Clin Oncol 22: 450-452
20. Thomas AL, Cox G, Sharma RA, Steward WP, Shields F, Jeyapalan K, Muller S, O'Byrne KJ (2000) Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study. Eur J Cancer 36: 2329-2334
21. Underhill CR, Parnis FX, Highley MS, Ahern J, Harper PG, Hansen H, Lund B, Dombernowsky P, Hirsch F, Hansen M, Carmichael J, Williams C (2001) Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer. Anticancer Drugs 12: 647-652
22. Vasey P (2001) Preliminary results of the SCOTROC II trial: a phase III comparison of paclitaxel-carboplatin (PC) and docetaxel-carboplatin (DC) as first-line chemotherapy for Stage Ic-IV epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 20: 202a (abstract 804)
23. Vasey PA (2002) Survival and longer-term toxicity results of the SCOTROC study: docetaxel-carboplatin (DC) vs paclitaxel-carboplatin (PC) in epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 21: 202a (abstract 804)
24. Vasey P, Atkinson R, Osborne R, Parkin D, Paul S, Coleman R, Paul J, Lewsley EA, Kaye S, Rustin G (2003) Carboplatin (Cb) followed sequentially by docetaxel (D)+/-gemcitabine (G) in ovarian, peritoneal and fallopian tube cancers; results of SCOTROC 2A. Proc Am Soc Clin Oncol 22, (abstract 804)
25. Von Minckwitz G, Bauknecht T, Visseren-Grul CM, Neijt JP (1999) Phase II study of gemcitabine in ovarian cancer. Ann Oncol 10: 853-855